Skip to main content
OpenTrials
Completed

NCT Number: NCT05988567

Efficacy Testing of Melon Oil Olive Pressed Candy Products

To assess melon and oil olive pressed candy on skin condition improvement

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Skin Condition Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chia Nan University of Pharmacy & Science

Tainan, Taiwan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adults aged above 18 years old
  • ITA° value 20°-41°

Exclusion criteria

  • Involuntary subjects.
  • Subjects who have a history of skin diseases such as psoriasis, eczema, atopic dermatitis, severe acne; or suffer from other chronic systemic disease.
  • Those with known cosmetic, drug or food allergies.
  • Female who is pregnant or nursing or planning to become pregnant during the course of the study.
  • Subjects who have taken oral or topical corticosteroids and other anti-inflammatory drugs in the past 1 month.
  • Use of any products or drugs that affect skin color such as fruit acid, salicylic acid (such as Hydroquinone preparations) in the past 2 months.
  • In the past 3 months, the test site has used retinoic acid preparations or undergone chemical peeling, laser, pulse light and other medical aesthetic therapists
  • Subjects who can not avoid long-term sun exposure

Treatment and study plan

Placebo candy

Dietary Supplement

consume 2 tablets per day

melon and oil olive pressed candy

Dietary Supplement

consume 2 tablets per day

Other names: Melon, oil olive and pomegranate blend pressed candy

Primary outcomes

  1. The change of skin wrinkles

    Time frame: Change from Baseline skin wrinkles at 12 weeks

    VISIA Complexion Analysis System was utilized to measure skin wrinkles. Units: arbitrary units

  2. The change of skin texture

    Time frame: Change from Baseline skin texture at 12 weeks

    VISIA Complexion Analysis System was utilized to measure skin texture. Units: arbitrary units

  3. The change of skin melanin index

    Time frame: Change from Baseline skin melanin index at 12 weeks

    Mexameter® MX18 was utilized to measure skin melanin index. Units: arbitrary units

  4. The change of skin erythema index

    Time frame: Change from Baseline skin erythema index at 12 weeks

    Mexameter® MX18 was utilized to measure skin erythema index. Units: arbitrary units

  5. The change of skin L* value

    Time frame: Change from Baseline L* value at 12 weeks

    Chroma Meter MM500 was utilized to measure skin L* value. Units: arbitrary units

  6. The change of skin b* value

    Time frame: Change from Baseline b* value at 12 weeks

    Chroma Meter MM500 was utilized to measure skin b* value. Units: arbitrary units

  7. The change of skin ITA° value

    Time frame: Change from Baseline ITA° value at 12 weeks

    Chroma Meter MM500 was utilized to measure skin ITA° value. Units: arbitrary units

  8. The change of skin spots

    Time frame: Change from Baseline skin spots at 12 weeks

    VISIA Complexion Analysis System was utilized to measure skin spots. Units: arbitrary units

  9. The change of skin UV spots

    Time frame: Change from Baseline skin UV spots at 12 weeks

    VISIA Complexion Analysis System was utilized to measure skin UV spots. Units: arbitrary units

  10. The change of skin brown spots

    Time frame: Change from Baseline skin brown spots at 12 weeks

    VISIA Complexion Analysis System was utilized to measure skin brown spots. Units: arbitrary units

Secondary outcomes

  1. The change of TEAC of blood

    Time frame: Change from Baseline TEAC at 12 weeks

    Venous blood was sampled to measure TEAC

  2. The change of SOD of blood

    Time frame: Change from Baseline SOD at 12 weeks

    Venous blood was sampled to measure SOD

  3. The change of GSH-Px of blood

    Time frame: Change from Baseline GSH-Px at 12 weeks

    Venous blood was sampled to measure GSH-Px

Other outcomes

  1. The change of self-assessment skin and hair condition

    Time frame: Change from Baseline skin and hair condition at 12 weeks

    A self-assessment questionnaire was collected to evaluate skin and hair condition

Sponsors and collaborators

Lead sponsor

TCI Co., Ltd.

Industry

Registry information

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Aug 14, 2023
Registry last updated
Feb 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.